Additive Manufacturing Technologies (AMT)
> Zum Inhalt

 

Project Information:

 

This project has received funding from the European Union’s Horizon 2020 research and innovation programme EIC Pathfinder under grant agreement 964955.

 

 

 

The INCITE project aims to improve current approaches for cancer immunotherapy by generating more robust and active memory phenotypes of anti-cancer T cells, such as CAR T or TCR- transgenic T cells. We will achieve this through construction of a microenvironment, in the form of an active immune niche that keeps anti-cancer T cells strong, vigilant and persistent both during preparation of the cells outside the body, and after being given to patients. We will describe and recapitulate the microenvironment of the niches that gives the most potent cells for the task of eradicating the cancer.

INCITE is a multidisciplinary project that combines competences in microfluidic modelling and high-resolution 3D microfabrication, basic molecular cell immunology, tissue engineering, bioinformatics, experimental and translational cancer immunotherapy and together with communication experts, we will embark on the ambition of transforming cell mediated immunotherapy of cancers for the future.


Partner Organizations:

  • NTNU NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET,Trondheim, Norway (Coordinator)
  • UPNANO GmbH,Wien Austria
  • TECHNISCHE UNIVERSITÄT Wien,Austria,
  • MEDIZINISCHE UNIVERSITÄT,Innsbruck, Austria,
  • OSPEDALE SAN RAFFAELE, Milano, Italy
  • DE DUVE INSTITUTE,Brussels, Belgium
  • STIFTUNG REGENSBURGER CENTRUM FUR INTERVENTIONELLE IMMUNOLOGIE,regensburg Germany,
  • BOUKJE.COM CONSULTING BV, Simpelveld, Netherlands

Links: https://cordis.europa.eu/project/id/964955